Kim S, Nadel JA. Fibrinogen binding to ICAM-1 promotes EGFR-dependent mucin production in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 297: L174 -L183, 2009. First published May 8, 2009 doi:10.1152/ajplung.00032.2009.-Mucous hypersecretion is a serious feature of chronic airway diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Although mucins are produced via activation of an EGF receptor (EGFR) signaling cascade, the mechanisms leading to exaggerated mucin production in mucous hypersecretory diseases are unknown. Because expression of ICAM-1 and of the ICAM-1 ligand fibrinogen is increased in the airways of subjects with mucous hypersecretory diseases, we hypothesized that fibrinogen binding to ICAM-1 could increase EGFR-dependent mucin production in human airway (NCI-H292) epithelial cells. Consistent with this hypothesis, we found that an ICAM-1 neutralizing antibody and an ICAM-1(8 -22) peptide that binds fibrinogen decreased mucin production induced by the EGFR ligand transforming growth factor (TGF)-␣ dosedependently. Exogenous fibrinogen and a fibrinogen(117-133) peptide that binds ICAM-1 rescued mucin production in cells treated with the ICAM-1(8 -22) peptide. Surprisingly, the ICAM-1(8 -22) peptide increased EGFR phosphotyrosine and phospho-ERK1/2 in cells treated with TGF-␣. The ICAM-1(8 -22) peptide-induced increases in EGFR phosphotyrosine and phospho-ERK1/2 were prevented by exogenous fibrinogen, by the fibrinogen(117-133) peptide, and by selective inhibitors of phospholipase C (PLC), protein kinase C (PKC)-␣/␤, and metalloproteases. These results suggest that fibrinogen binding to ICAM-1 promotes mucin production by decreasing TGF-␣-induced EGFR and ERK1/2 activation and that the fibrinogen-ICAM-1-dependent decrease in EGFR and ERK1/2 activation occurs via inhibition of an early positive feedback pathway involving PLCand PKC-␣/␤-dependent metalloprotease activation and subsequent metalloprotease-dependent EGFR reactivation.
ICAM-1 is expressed on the surface of various cells including airway epithelial cells, and its expression in airway epithelium is increased in asthma (4), COPD (17) , and cystic fibrosis (27) . ICAM-1 is induced in airway epithelial cells by cytokines including IL-1␤ (65) and TNF-␣ (65) . ICAM-1 plays a classic role in mediating cell-cell adhesion, enabling leukocytes that express the ICAM-1 ligands LFA-1 and Mac-1 to migrate to sites of inflammation (59) . ICAM-1 also serves as a receptor for respiratory pathogens including rhinoviruses (60) and Haemophilus influenzae (2) . In addition to these established roles in cell-cell and cell-pathogen adhesion, there is growing evidence that ICAM-1 is involved in cell signaling (22, 47) .
Fibrinogen, an ICAM-1 ligand, is a protein produced by hepatocytes and by other cells including airway epithelial cells as part of inflammatory responses (25, 57) . Fibrinogen is present in mucous plugs, is increased in the airways of subjects with acute severe asthma (67) , COPD (45) , and cystic fibrosis (64) , and has been shown to induce ICAM-1-dependent signaling in endothelial (34, 47) and immune (22) cells. The effects of fibrinogen binding to ICAM-1 on airway epithelial cells are unknown.
We hypothesized that fibrinogen binding to ICAM-1 could increase EGFR-dependent mucin production in airway epithelial cells. Because E-cadherin (28) and type I collagen receptors (39) have been reported to increase EGFR-dependent mucin production (i.e., cell differentiation) by decreasing EGFR and ERK1/2 activation, we also hypothesized that fibrinogen binding to ICAM-1 could increase mucin production via a mechanism that results in decreased EGFR and ERK1/2 activation. We tested this hypothesis in transformed human airway (NCI-H292) epithelial cells because, unlike normal human airway epithelial cells (35, 57) , NCI-H292 cells express high levels of ICAM-1 (63) and fibrinogen constitutively. Consistent with our hypothesis, we show here that binding of airway epithelium-derived fibrinogen to ICAM-1 promotes EGFR ligand transforming growth factor (TGF)-␣-dependent mucin production in NCI-H292 cells. In addition, we show that fibrinogen binding to ICAM-1 decreases TGF-␣-induced EGFR and ERK1/2 activation via inhibition of an early positive feedback loop that involves PLC-and PKC-␣/ ␤-dependent activation of a metalloprotease and subsequent metalloprotease-dependent EGFR reactivation.
MATERIALS AND METHODS
Reagents. TGF-␣, AG-1478, AG-1295, PD-98059, GM-6001, TNF-␣ proteinase inhibitor-1 (TAPI-1), U-73122, U-73343, calphostin C, Gö-6976, rottlerin, and pp2 were purchased from Calbiochem (San Diego, CA). Leupeptin, aprotinin, and human fibrinogen were purchased from Sigma-Aldrich (St. Louis, MO).
Synthetic peptides. Peptides with amino acid sequences corresponding to regions of the fibrinogen-ICAM-1 binding site characterized by D'Souza et al. (15) were synthesized, purified by HPLC, and confirmed by mass spectrometry (Sigma-Genosys, The Woodlands, TX). Specific peptide sequences were ICAM-1 (8 -22) : KVILPRGGS VLVTCS; ICAM-1 (130 -145): REPAVGEPAEVTTTV; fibrinogen(117-133): NNQKIVNLKEKVAQLEA; and scrambled fibrinogen peptide (Fg scr)(117-133): ALENAEVQNLVKKIQKN.
Cell culture. Cells from the human pulmonary mucoepidermoid carcinoma cell line NCI-H292 were grown to confluence in RPMI 1640 medium containing 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 mg/ml), and 25 mM HEPES at 37°C in a humidified 5% CO 2 water-jacketed incubator. Because cell lines such as NCI-H292 show variability in their responses to stimuli and inhibitors at different passages, all experiments were performed with cells from passages 80 -90.
Blockade of fibrinogen binding to ICAM-1. To disrupt divalent cation-dependent binding interactions mediated by ICAM-1 (36), confluent cultures of NCI-H292 cells were washed with Ca 2ϩ -, Mg 2ϩ -free PBS and then incubated with RPMI 1640 medium containing 4 mM EDTA for 30 min at 37°C ("divalent cation switch"). Subsequently, divalent cation-dependent contacts were allowed to reform in serum-free RPMI 1640 medium for 2 h at 37°C (44) . To prevent reformation of interactions involving the first extracellular domain of ICAM-1, a mouse monoclonal ICAM-1 neutralizing antibody [clone 15.2 (Calbiochem) or clone RR1/1 (Biosource, Camarillo, CA)] was included in the serum-free medium. The ICAM-1 neutralizing antibody did not affect cell viability (data not shown). As an antibody control, cells were incubated with a mouse monoclonal antibody to CD68 (IgG1; DAKO, Carpinteria, CA). This control antibody did not affect EGFR tyrosine phosphorylation (data not shown).
To examine the effects of fibrinogen binding to ICAM-1, cells were incubated with various concentrations of synthetic peptides after divalent cation switch, including ICAM-1 (8 -22) peptide (which binds fibrinogen specifically and prevents its binding to ICAM-1), ICAM-1(130 -145) peptide (which does not bind fibrinogen), fibrinogen(117-133) peptide (which binds the first extracellular domain of ICAM-1 specifically), or Fg scr. Alternatively, cells were incubated with exogenous human fibrinogen after divalent cation switch. Cells were then stimulated with the EGFR ligand TGF-␣ (5 ng/ml; 24 h for mucin measurements and for various times up to 60 min for measurements of EGFR tyrosine phosphorylation). Cells were serum starved overnight before divalent cation switch for measurement of EGFR tyrosine phosphorylation. In inhibition studies, cells were pretreated with an EGFR-selective tyrosine kinase inhibitor (AG-1478; 1 M), a selective PDGF receptor tyrosine kinase inhibitor (AG-1295; 10 M), a selective MEK inhibitor (PD-98059; 30 M), a general metalloprotease inhibitor (GM-6001; 10 M), a more selective TNF-␣-converting enzyme (TACE) inhibitor (TAPI-1; 30 M), a cysteine protease inhibitor (leupeptin; 50 M), a serine protease inhibitor (aprotinin; 10 g/ml), a selective Src tyrosine kinase inhibitor (pp2; 10 nM), a PLC inhibitor (U-73122; 1 M), an inactive analog of the PLC inhibitor (U-73343; 1 M), a general PKC inhibitor (calphostin C; 200 nM), a selective PKC-␣/␤ inhibitor (Gö-6976; 50 nM), or a selective PKC-␦/ inhibitor (rottlerin; 5 M), 30 min before the addition of TGF-␣.
EGFR tyrosine dephosphorylation was measured as described by Böhmer et al. (7) . After blockade of fibrinogen-ICAM-1 binding and stimulation with TGF-␣ for 10 min, an EGFR-selective tyrosine kinase inhibitor (AG-1478; 1 M) was added to block further EGFR tyrosine phosphorylation. Dephosphorylation was stopped by lysis of the cells at various times after addition of AG-1478. Quantitative immunoassay of EGFR phosphotyrosine was performed as described below.
Immunoassay of MUC5AC protein. MUC5AC protein in cell lysates and in cell culture supernatants was measured by ELISA as described previously (62 Immunoprecipitation and immunoblotting. After various treatments, cells were lysed on ice in PBS lysis buffer containing 1% Triton X-100, 1% deoxycholic acid, 50 mM NaF, 1 mM sodium orthovanadate, and protease inhibitors (Complete Mini; Roche, Mannheim, Germany). Lysates were precleared by centrifugation at 14,000 rpm for 5 min at 4°C. Protein concentration was measured with a bicinchoninic acid-based protein assay kit (Pierce, Rockford, IL). For immunoprecipitation, aliquots of cell lysates from 1 ϫ 10 5 cells were immunoprecipitated with a monoclonal anti-EGFR antibody (Ab-5; Calbiochem), a rabbit polyclonal anti-ERK1/2 antibody (Calbiochem), or a goat polyclonal anti-fibrinogen antibody (G-20; Santa Cruz Biotechnology) and 20 l of protein A/G PLUS-agarose beads (Santa Cruz Biotechnology) for 16 h at 4°C. Immunoprecipitates were washed with PBS, suspended in SDS sample buffer, boiled for 5 min, and separated by electrophoresis on an SDS-7.5% polyacrylamide gel. Proteins were then transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Richmond, CA), which were blocked with Tris-buffered saline containing either 1% fat-free skim milk and 1% BSA (for blotting with anti-phosphotyrosine antibodies) or 5% fat-free skim milk (for blotting with other antibodies) overnight at 4°C and then blotted with monoclonal anti-phosphotyrosine antibodies (PY99 or PY20; Santa Cruz Biotechnology), a monoclonal anti-EGFR antibody (Ab-5; Calbiochem), a monoclonal anti-phospho-ERK1/2 antibody (E-4; Santa Cruz Biotechnology), a rabbit polyclonal anti-ERK1/2 antibody (Calbiochem), or a monoclonal anti-ICAM-1 antibody (clone 15.2; Calbiochem). Bound antibody was visualized with enhanced chemiluminescence (Amersham, Piscataway, NJ). Immunoblots were scanned, and band intensities were quantified with NIH Image 1.63 software (developed at the National Institutes of Health and available for free download at rsbweb.nih.gov).
Immunoassay of EGFR phosphotyrosine. Total EGFR phosphotyrosine was measured by sandwich ELISA using a kit according to the manufacturer's instructions (DuoSet IC; R&D Systems).
Statistical analysis. All data are expressed as means Ϯ SE. Oneway ANOVA was used to determine statistically significant differences between groups (P Ͻ 0.05 for the null hypothesis).
RESULTS

ICAM-1 neutralizing antibody decreases TGF-␣-induced mucin production.
The EGFR ligand TGF-␣ (5 ng/ml, 24 h) increased mucin production 3.5-fold in human airway (NCI-H292) epithelial cells (Fig. 1A) . Mucin production in the control state was 1.24 Ϯ 0.17 g MUC5AC mucin/g protein (n ϭ 5). An ICAM-1 neutralizing antibody that prevents ICAM-1 ligand binding to the first extracellular domain of ICAM-1 decreased TGF-␣-induced mucin production dosedependently by 60% (Fig. 1A) . In the control state, the ICAM-1 antibody had no significant effect on mucin production (Fig.  1A) . A second ICAM-1 neutralizing antibody that blocks ligand binding to the first extracellular domain produced similar results, whereas an isotype-matched antibody had no effect on TGF-␣-induced mucin production (Fig. 1A) . These results suggest that the binding of an ICAM-1 ligand to the first extracellular domain of ICAM-1 increases TGF-␣-induced mucin production.
Fibrinogen increases TGF-␣-induced mucin production via binding to ICAM-1. Because the ICAM-1 ligand fibrinogen is produced by airway epithelial cells as part of inflammatory responses (25, 57) and because fibrinogen binds to the first extracellular domain of ICAM-1 (15), we examined whether fibrinogen increases mucin production induced by TGF-␣ ICAM-1-dependently. An ICAM-1 (8 -22) peptide [which binds fibrinogen specifically and prevents its binding to ICAM-1 (15)] decreased TGF-␣-induced mucin production at 24 h dose-dependently (Fig. 1B) ; a structurally comparable ICAM-1(130 -145) peptide that does not bind fibrinogen (15) had no effect on mucin production (Fig. 1B) , implicating fibrinogen binding to ICAM-1 in mucin production induced by TGF-␣. In the control state, the ICAM-1(8 -22) peptide had no significant effect on mucin production (Fig. 1B) . Exogenous fibrinogen "rescued" TGF-␣-induced mucin production in cells treated with the ICAM-1(8 -22) peptide dose-dependently (Fig.  1C) . In addition, a fibrinogen peptide(117-133) that binds ICAM-1 specifically and that does not bind ␤ 3 -integrin, another cell surface fibrinogen receptor (51), also rescued TGF-␣-induced mucin production in cells treated with the ICAM-1(8 -22) peptide dose-dependently (Fig. 1C) . A control fibrinogen(117-133 scrambled) peptide had no rescue effect (Fig.  1C) . To confirm that ICAM-1 binds fibrinogen in NCI-H292 cells, we examined fibrinogen-containing protein complexes for the presence of ICAM-1: ICAM-1 coimmunoprecipitated with fibrinogen (Fig. 2, lane 1) . Pretreatment with the ICAM-1(8 -22) peptide decreased ICAM-1 binding to fibrinogen (Fig.  2, lane 2) , while the control ICAM-1(130 -145) peptide had no effect on this interaction (Fig. 2, lane 3) . Pretreatment of cells treated with the ICAM-1 (8 -22) peptide with exogenous fibrinogen restored ICAM-1 binding to fibrinogen (Fig. 2, lane 4) . Together, these results implicate specific binding of fibrinogen to ICAM-1 in TGF-␣-induced mucin production.
Fibrinogen binding to ICAM-1 decreases TGF-␣-induced EGFR and ERK1/2 activation. Because non-EGFR receptors can promote EGFR-dependent cell differentiation by decreas-
ing EGFR (28, 39) and ERK1/2 (31, 39) activation, we next examined whether fibrinogen binding to ICAM-1 similarly decreases TGF-␣-induced EGFR and ERK1/2 activation. The ICAM-1 (8 -22) peptide, which binds fibrinogen and prevents its binding to ICAM-1, significantly increased TGF-␣-induced EGFR phosphotyrosine at 5 and 10 min after addition of TGF-␣ (Fig. 3A) without affecting levels of total EGFR (data not shown). This peptide had no significant effect on EGFR phosphotyrosine at later times after TGF-␣ stimulation (30 and 60 min; Fig. 3A) . Addition of exogenous fibrinogen or the fibrinogen(117-133) peptide prevented the ICAM-1 (8 -22) peptide-dependent increase in TGF-␣-induced EGFR phosphotyrosine at 10 min (Fig. 3B) , while the control fibrinogen(117-133 scrambled) peptide had no effect on the ICAM-1(8 -22) peptide-dependent increase (Fig. 3B) .
Because the effect of preventing fibrinogen binding to ICAM-1 on EGFR activation was maximal 10 min after stimulation with TGF-␣, ERK1/2 activation was examined at 10 min: TGF-␣ markedly increased phospho-ERK1/2 at 10 min (Fig. 3C) . Pretreatment with the ICAM-1(8 -22) peptide increased TGF-␣-induced phospho-ERK1/2; the peptide alone had no significant effect (Fig. 3C) . Addition of exogenous fibrinogen or the fibrinogen(117-133) peptide prevented the ICAM-1(8 -22) peptide-dependent increase in phospho-ERK1/2 (Fig. 3C) , while the control fibrinogen(117-133 scrambled) peptide had no effect on this increase (Fig. 3C) . Together, these results show that the binding of fibrinogen to ICAM-1 decreases the amplitude of TGF-␣-induced EGFR and ERK1/2 activation.
Preventing binding of fibrinogen to ICAM-1 increases phosphorylation of EGFR tyrosines but does not decrease dephosphorylation. Next, we investigated potential roles for either decreased EGFR tyrosine dephosphorylation (i.e., decreased EGFR-directed phosphatase activity) or increased EGFR tyrosine phosphorylation in the ICAM-1(8 -22) peptide-dependent increase in TGF-␣-induced EGFR activation. We employed a method described by Böhmer et al. (7) to monitor the dephosphorylation rate of receptor tyrosine kinases. After stimulation with TGF-␣ for 10 min, further EGFR tyrosine kinase activity was blocked with an EGFR-selective tyrosine kinase inhibitor (AG-1478; 1 M) and the rate of dephosphorylation measured by analyzing the amount of EGFR phosphotyrosine at various times (1, 2, and 5 min) after EGFR inhibition. The ICAM-1 (8 -22) peptide increased the amount of TGF-␣-induced EGFR phosphotyrosine at 10 min (Fig. 4) . After inhibition of further EGFR tyrosine phosphorylation with AG-1478, EGFR phosphotyrosine levels decreased rapidly in the absence or presence of the ICAM-1(8 -22) peptide, reaching control levels between 1 and 2 min of EGFR inhibition (Fig. 4) . These results suggest that the ICAM-1(8 -22) peptide-dependent increase in EGFR phosphotyrosine does not involve decreased dephosphorylation of EGFR. Furthermore, because EGFR inhibition rapidly led to equal levels of EGFR phosphotyrosine in cells treated or not treated with the ICAM-1 (8 -22) peptide (Fig. 4) , these results also suggest that the peptideinduced increase in EGFR phosphotyrosine involves increased EGFR-dependent tyrosine phosphorylation.
Metalloprotease mediates fibrinogen-ICAM-1 blockade-dependent increase in EGFR and ERK1/2 activation. Because EGFR ligands have been shown to induce the metalloproteasedependent cleavage and release of EGFR proligands (3, 19, 40), we hypothesized that the fibrinogen-ICAM-1 blockadedependent increase in TGF-␣-induced EGFR and ERK1/2 activation may involve such a rapid metalloprotease-dependent feedback loop. The general metalloprotease inhibitor GM-6001 (10 M) or a more selective TACE inhibitor, TAPI-1 (30 M), completely prevented the ICAM-1(8 -22) peptide-dependent increase in TGF-␣-induced EGFR phosphotyrosine (Fig. 5A ) and phospho-ERK1/2 (Fig. 5B) at 10 min. These inhibitors had no significant effect on EGFR phosphotyrosine (Fig. 5A) or phospho-ERK1/2 (Fig. 5B ) in cells treated with TGF-␣ alone. A cysteine protease inhibitor (leupeptin; 50 M), a serine protease inhibitor (aprotinin; 10 g/ml), or a selective src kinase inhibitor (pp2; 10 nM) had no significant effect on EGFR phosphotyrosine or phospho-ERK1/2 in cells treated with TGF-␣ and ICAM-1(8 -22) peptide or with TGF-␣ alone (data not shown). Together, these results implicate a metalloprotease, probably TACE, in the ICAM-1(8 -22) peptide-dependent increase in TGF-␣-induced EGFR and ERK1/2 activation. (11), and because PKC activates the metalloprotease TACE (54), we examined whether the ICAM-1(8 -22) peptide-dependent increase in TGF-␣-induced EGFR and ERK1/2 activation was PLCand PKC dependent. The PLC-specific inhibitor U-73122 (1 M) completely prevented the ICAM-1(8 -22) peptidedependent increase in TGF-␣-induced EGFR phosphotyrosine (Fig. 6A ) and phospho-ERK1/2 (Fig. 6B ) at 10 min; the inactive analog U-73343 (1 M) had no effect (data not shown). Pretreatment with the general PKC inhibitor calphostin C (200 nM) or the PKC-␣/␤ inhibitor Gö-6976 (50 nM), but not the PKC-␦/ inhibitor rottlerin (5 M), also completely prevented the ICAM-1 (8 -22) peptide-dependent increase in TGF-␣-induced EGFR phosphotyrosine (Fig. 6A) and phospho-ERK1/2 (Fig. 6B) at 10 min. Pretreatment of cells with U-73122, calphostin C, rottlerin, or Gö-6976 had no significant effect on EGFR phosphotyrosine or phospho-ERK1/2 at 10 min in cells treated with TGF-␣ alone (data not shown). These results suggest that PLC and PKC-␣/␤ mediate the fibrinogen-ICAM-1 blockade-dependent increase in TGF-␣-induced EGFR and ERK1/2 activation.
PLC and PKC-␣/␤ mediate fibrinogen-ICAM-1 blockadedependent increase in EGFR and ERK1/2 activation. Because EGFR activates PLC, which results in activation of PKC
DISCUSSION
We show here that binding of the ICAM-1 ligand fibrinogen to ICAM-1 promotes TGF-␣-induced mucin production in human airway (NCI-H292) epithelial cells. We examined NCI-H292 cells because, unlike normal human airway epithelial cells (35, 57) , NCI-H292 cells express high levels of ICAM-1 (6, 63) and fibrinogen (Fig. 2) in the constitutive state. To the best of our knowledge, this is the first study to show that fibrinogen binding to ICAM-1 has an effect on EGFR signaling and on EGFR-dependent cell responses. Fibrinogen binding to ICAM-1 decreased TGF-␣-induced EGFR and ERK1/2 activation. This decrease in EGFR and ERK1/2 activation occurred via the fibrinogen-and ICAM-1-dependent inhibition of an early positive feedback pathway involving PLC-, PKC-␣/ ␤-, and metalloprotease-dependent EGFR reactivation. Our results suggest that fibrinogen binding to ICAM-1 modifies EGFR signaling.
Airway epithelial cells express the EGFR ligands EGF, TGF-␣, amphiregulin, and heparin binding (HB)-EGF (48) . In the epithelium, EGFR proligands are synthesized as membrane-anchored molecules that are activated by proteolytic cleavage. Although all EGFR ligands exert their biological functions via signals downstream of EGFR binding and activation, whether certain EGFR ligands promote EGFRdependent mucin production more than others is not known, but is an important issue. We examined TGF-␣ because of the extensive literature showing the role of TGF-␣ in mucin production in vivo and in vitro (8, 29, 55, 56, 62) . In NCI-H292 cells, cleavage of pro-HB-EGF and of pro-amphiregulin has also been shown to induce mucin production (13, 32) , raising the possibility that fibrinogen binding to ICAM-1 could modify EGFR signaling and responses induced by EGFR ligands besides TGF-␣.
First, we examined the effects of ICAM-1 ligand binding to ICAM-1 on EGFR-dependent mucin production in NCI-H292 cells. An ICAM-1 neutralizing antibody that prevents binding of ligands to the first extracellular immunoglobulin-like domain of ICAM-1 decreased TGF-␣-induced mucin production dose-dependently, implicating binding of an endogenous ICAM-1 ligand to the first extracellular domain of ICAM-1 in this EGFR-dependent response. In contrast, the ICAM-1 neutralizing antibody had no significant effect on TGF-␣-induced production in normal human bronchoepithelial cells (data not shown), consistent with the lack of constitutive ICAM-1 expression in normal airway epithelial cells (35) . Although a role Fig. 5 . Effect of metalloprotease inhibition on ICAM-1(8 -22) peptide-dependent increase in EGFR and ERK1/2 activation. A: EGFR-P was measured by ELISA in confluent cultures of NCI-H292 cells that were serum starved overnight and then incubated for 10 min with medium alone (ϪTGF-␣; control), added TGF-␣ (5 ng/ml; ϩTGF-␣), or with added TGF-␣ ϩ either the general metalloprotease inhibitor GM-6001 (GM; 10 M) or the more selective TNF-␣-converting enzyme (TACE) inhibitor TAPI-1 (TAPI; 30 M). Alternatively, cultures were incubated with added TGF-␣ ϩ 100 M ICAM-1(8 -22) peptide or with added TGF-␣ ϩ ICAM-1(8 -22) peptide ϩ either GM-6001 or TAPI-1. Results are expressed as ng EGFR-P/10 5 cells. Values are means Ϯ SD; n ϭ 3. *P Ͻ 0.05 compared with control; # P Ͻ 0.05 compared with ϩTGF-␣ alone. B: p-ERK1/2 and ERK1/2 were measured by immunoblot in confluent cultures of NCI-H292 cells that were treated as in A. Band intensities were measured with densitometric analysis (NIH Image) and expressed as OD units. p-ERK1/2 levels are expressed as the ratio of p-ERK1/2 to ERK1/2 band intensities, with p-ERK1/2/ERK1/2 of the control bands set arbitrarily to 1. Values are means Ϯ SD; n ϭ 3. *P Ͻ 0.05 compared with control;
# P Ͻ 0.05 compared with ϩTGF-␣ alone.
for ICAM-1 in mucin production has not been described previously, ICAM-1 expression has been shown to be increased in cultured airway epithelial cells by stimuli that also induce mucin production, such as IL-1␤ (65), IL-13 (5), TNF-␣ (65), and LPS (42), and in the airways of subjects with mucous hypersecretory diseases including asthma (4), COPD (17) , and cystic fibrosis (27) , suggesting that ICAM-1 could promote mucin production in vitro and mucous hypersecretion in vivo. Next, we examined whether ICAM-1 promotes EGFR-dependent mucin production via binding to fibrinogen. We examined fibrinogen for the following reasons: first, fibrinogen has been shown to bind to the first extracellular domain of ICAM-1 (15); second, the binding of fibrinogen to ICAM-1 has been shown to induce cell signaling (22, 34, 47) ; and third, fibrinogen has been found on the airway mucosal surface in rodent models of allergic airway inflammation (18, 67) and in the airways of subjects with acute severe asthma (67), COPD (45) , and cystic fibrosis (64) . In airways, fibrinogen has been shown to inactivate surfactant (53) and to induce airway hyperresponsiveness (67); a potential role for ICAM-1 in these fibrinogen effects was not examined in those studies. In the present study, we found that, like the ICAM-1 neutralizing antibody, an ICAM-1 (8 -22) peptide that prevents binding of fibrinogen to ICAM-1 decreased TGF-␣-induced mucin production dose-dependently. ICAM-1 can be cleaved by various proteases to form soluble ICAM-1 (10, 20, 66) . We speculate that, like the ICAM-1(8 -22) peptide, soluble ICAM-1 may bind fibrinogen, preventing it from binding to ICAM-1 on the cell surface. Because fibrinogen also binds ␤ 3 -integrin (51), we examined the effects of a fibrinogen(117-133) peptide that binds ICAM-1 and that does not bind ␤ 3 -integrin on EGFRdependent mucin production. This peptide (or exogenous fibrinogen) rescued mucin production in cells treated with the ICAM-1 (8 -22) peptide, implicating binding of endogenous fibrinogen to ICAM-1, and not to another fibrinogen receptor, in TGF-␣-induced mucin production.
In addition to fibrinogen, other ICAM-1 ligands that are produced by airway epithelial cells include MUC1 mucin (49) and hyaluronan (38) . The effects of hyaluronan binding to ICAM-1 in airway epithelial cells are unknown. In contrast, MUC1 has been shown to bind to EGFR and to increase EGF-induced ERK1/2 activation (52), implicating MUC1 in the modulation of EGFR signals. In support of this idea, MUC1 has been shown to decrease E-cadherin-mediated intercellular adhesion (33), possibly decreasing E-cadherin-dependent EGFR dephosphorylation, and MUC1 has been shown to bind Grb2 (43) , resulting in activation of the Ras-Raf-MEK-ERK1/2 pathway. MUC1 protein is present on the surface of NCI-H292 cells (unpublished results), suggesting that binding of MUC1 to ICAM-1 could affect EGFR-dependent cell responses.
How does fibrinogen binding to ICAM-1 promote EGFRdependent cell differentiation (i.e., mucin production)? It is well known that the amplitude of EGFR and ERK1/2 phosphorylation determines cell responses in response to EGFR activation (37, 50, 69) . Previous studies have shown that signals from cell-cell (E-cadherin) and cell-matrix (type I collagen) interactions promote EGFR-dependent mucin production via mechanisms that decrease EGFR ligand-induced EGFR and ERK1/2 activation (28, 31, 39) . In contrast, block- ade of E-cadherin-mediated cell-cell contacts and signals from fibronectin receptors increases EGFR ligand-induced EGFR and ERK1/2 activation, inhibiting EGFR-dependent mucin production in airway epithelial cells (28 (14, 70) . In contrast, the present findings suggest that ICAM-1 modulates ERK1/2 activation and subsequent mucin production EGFR-dependently. In addition, while ICAM-1 activation has been shown to modulate signaling downstream from the T-cell receptor (12, 21) , the present findings are the first to show an effect of ICAM-1 on EGFR signaling in epithelial cells and are consistent with the idea that lower levels of EGFR and ERK1/2 activation promote EGFR-dependent cell differentiation (i.e., mucin production).
Signals from cell-cell interactions (e.g., E-cadherin) have been shown to decrease EGFR ligand-induced EGFR activation via EGFR-directed protein tyrosine phosphatase activity (28, 58) . ICAM-1 has been shown to activate Src homology 2-containing protein tyrosine phosphatase-2 (Shp-2), a phosphatase that dephosphorylates EGFR (1), in endothelial cells (46, 68) . Therefore, we hypothesized that fibrinogen binding to ICAM-1 could decrease TGF-␣-induced EGFR tyrosine phosphorylation via a phosphatase, perhaps Shp-2, in airway epithelial cells. We found that, in the absence of further EGFR tyrosine phosphorylation, EGFR-directed protein tyrosine phosphatase activity reduced TGF-␣-induced EGFR phosphotyrosine to control levels within 1-2 min, consistent with the rapid EGFR tyrosine dephosphorylation (t 1/2 Ͻ 2 min) reported in confluent cultures of NCI-H292 cells (28) and in other cells (7) . In contrast to our hypothesis, preventing binding of endogenous fibrinogen to ICAM-1 did not decrease the rate of EGFR tyrosine dephosphorylation, implicating a mechanism other than increased EGFR-directed tyrosine phosphatase activity in the fibrinogen-ICAM-1-dependent decrease in EGFR activation.
Metalloproteases have been shown to cleave EGFR proligands and to release soluble ligands, making them available for binding to EGFR (61) . Because EGFR ligands have been shown to induce subsequent metalloprotease-dependent EGFR activation (3, 19) , we next examined whether the fibrinogen-ICAM-1 blockade-dependent increase in TGF-␣-induced EGFR phosphotyrosine involves metalloprotease-dependent EGFR rephosphorylation (i.e., a positive feedback loop). Consistent with this idea, we found that a general metalloprotease inhibitor (GM-6001) and a more selective inhibitor of TACE (TAPI-1) prevented the ICAM-1(8 -22) peptide-dependent increase in TGF-␣-induced EGFR phosphotyrosine, implicating a metalloprotease, probably TACE, in this process. TACE can be activated by a PKC-dependent mechanism in airway epithelial cells (54) . EGFR tyrosine phosphorylation leads to activation of PLC-␥, producing diacylglycerol and inositol trisphosphate, which activates PKC. We hypothesized that, in the presence of fibrinogen-ICAM-1 blockade, EGFR may activate TACE via PLC and PKC, leading to EGFR reactivation. Consistent with this hypothesis, we found that selective inhibition of PLC-␥ prevented the ICAM-1 (8 -22) peptidedependent increase in TGF-␣-induced EGFR phosphotyrosine and phospho-ERK1/2. In addition, selective inhibition of the Ca 2ϩ -dependent PKC-␣/␤ isozymes, but not the Ca 2ϩ -independent isozymes, also prevented the fibrinogen-ICAM-1 blockade-dependent increase in EGFR phosphotyrosine and phospho-ERK1/2. Thus fibrinogen binding to ICAM-1 decreases TGF-␣-induced EGFR and ERK1/2 activation via inhibition of an early positive feedback pathway involving PLC-and PKC-␣/␤-dependent EGFR reactivation, promoting mucin production (shown as a diagram in Fig. 7) .
We have not found an EGFR-dependent cell response that is increased because of the transient increase in EGFR and ERK1/2 activation caused by preventing fibrinogen binding to ICAM-1. In contrast to E-cadherin blockade (28) , preventing fibrinogen binding to ICAM-1 did not increase TGF-␣-induced cell proliferation (data not shown). In addition, preventing this interaction decreased TGF-␣-induced IL-8 production (data not shown). Studies to identify EGFR-dependent responses that are increased by preventing binding of fibrinogen to ICAM-1 are ongoing in our lab. In the future, we will confirm that fibrinogen binding to ICAM-1 increases EGFR-dependent mucin production in vivo, and we will examine the effects of other ICAM-1 ligands produced by epithelial cells (e.g., MUC1, hyaluronan) on ICAM-1-dependent regulation of EGFR.
In summary, we show here that 1) fibrinogen binding to ICAM-1 promotes EGFR-dependent mucin production in airway epithelial cells and 2) fibrinogen binding to ICAM-1 decreases TGF-␣-induced EGFR and ERK1/2 activation via Fig. 7 . Diagram outlining the role of fibrinogen binding to ICAM-1 in promotion of EGFR-dependent mucin production. When fibrinogen (Fg) is bound to ICAM-1, TGF-␣ (diamond) binding to EGFR results in EGFR tyrosine phosphorylation (small circles), phosphorylation of ERK1/2, and subsequent mucin production. When fibrinogen is prevented from binding to ICAM-1, an early positive feedback pathway is initiated: TGF-␣ binding to EGFR leads to activation of PLC, production of Ca 2ϩ , and activation of PKC-␣/␤ isoforms. PKC-␣/␤ leads to activation of a metalloprotease, probably TACE, enabling the catalytic domain (scissors) to cleave EGFR proligand. Soluble EGFR ligand binds to and activates EGFR, resulting in increased levels of EGFR phosphotyrosine (large circles) and phospho-ERK1/2 at 10 min compared with cells with intact fibrinogen-ICAM-1 interactions. This leads to decreased mucin production.
inhibition of a positive feedback pathway involving PLC-, PKC-␣/␤-, and metalloprotease-dependent EGFR reactivation. The present findings show that fibrinogen-ICAM-1 negatively modulates EGFR activation, leading to mucin production, and they suggest potential therapies for mucous hypersecretory diseases (e.g., asthma, COPD, and cystic fibrosis) characterized by increased levels of fibrinogen, ICAM-1, and EGFR in the airways.
